{"id":"https://openalex.org/W2118915687","doi":null,"title":"Phase II study of bevacizumab and temsirolimus combination therapy for recurrent glioblastoma multiforme.","display_name":"Phase II study of bevacizumab and temsirolimus combination therapy for recurrent glioblastoma multiforme.","publication_year":2013,"publication_date":"2013-04-01","ids":{"openalex":"https://openalex.org/W2118915687","mag":"2118915687","pmid":"https://pubmed.ncbi.nlm.nih.gov/23564811"},"language":"en","primary_location":{"id":"pmid:23564811","doi":null,"is_oa":false,"landing_page_url":"https://pubmed.ncbi.nlm.nih.gov/23564811","pdf_url":null,"source":{"id":"https://openalex.org/S4306525036","display_name":"PubMed","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Anticancer research","raw_type":"Clinical Trial, Phase II"},"volume":null,"type":"article","is_traditional":true,"indexed_in":["pubmed"],"open_access":{"is_oa":false,"oa_status":"closed","oa_url":null,"any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5077199450","display_name":"Ulrik Lassen","orcid":"https://orcid.org/0000-0002-3865-4574","observed_orcids":["https://orcid.org/0000-0002-3865-4574"]},"institutions":[{"id":"https://openalex.org/I2802709434","display_name":"Rigshospitalet","ror":"https://ror.org/03mchdq19","country_code":"DK","type":"healthcare","lineage":["https://openalex.org/I2802567020","https://openalex.org/I2802709434","https://openalex.org/I4210145385"]}],"countries":["DK"],"is_corresponding":false,"raw_author_name":"Ulrik Lassen","raw_affiliation_strings":["Department of Oncology, Rigshospitalet, Copenhagen, Denmark. ulrik.lassen@rh.regionh.dk"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Department of Oncology, Rigshospitalet, Copenhagen, Denmark. ulrik.lassen@rh.regionh.dk","institution_ids":["https://openalex.org/I2802709434"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5070373312","display_name":"Morten Mau\u2010S\u00f8rensen","orcid":"https://orcid.org/0000-0003-2235-1250","observed_orcids":["https://orcid.org/0000-0003-2235-1250"]},"institutions":[{"id":"https://openalex.org/I2802709434","display_name":"Rigshospitalet","ror":"https://ror.org/03mchdq19","country_code":"DK","type":"healthcare","lineage":["https://openalex.org/I2802567020","https://openalex.org/I2802709434","https://openalex.org/I4210145385"]}],"countries":["DK"],"is_corresponding":false,"raw_author_name":"Morten Sorensen","raw_affiliation_strings":["Department of Oncology, Rigshospitalet, Copenhagen, Denmark"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Department of Oncology, Rigshospitalet, Copenhagen, Denmark","institution_ids":["https://openalex.org/I2802709434"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5121328793","display_name":"T.B.B. Gaziel","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I2802709434","display_name":"Rigshospitalet","ror":"https://ror.org/03mchdq19","country_code":"DK","type":"healthcare","lineage":["https://openalex.org/I2802567020","https://openalex.org/I2802709434","https://openalex.org/I4210145385"]}],"countries":["DK"],"is_corresponding":false,"raw_author_name":"Tine Bernhardtsen Gaziel","raw_affiliation_strings":["Department of Oncology, Rigshospitalet, Copenhagen, Denmark"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Department of Oncology, Rigshospitalet, Copenhagen, Denmark","institution_ids":["https://openalex.org/I2802709434"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5087170219","display_name":"Benedikte Hasselbalch","orcid":"https://orcid.org/0009-0003-6514-2421","observed_orcids":["https://orcid.org/0009-0003-6514-2421"]},"institutions":[{"id":"https://openalex.org/I2802709434","display_name":"Rigshospitalet","ror":"https://ror.org/03mchdq19","country_code":"DK","type":"healthcare","lineage":["https://openalex.org/I2802567020","https://openalex.org/I2802709434","https://openalex.org/I4210145385"]}],"countries":["DK"],"is_corresponding":false,"raw_author_name":"Benedikte Hasselbalch","raw_affiliation_strings":["Department of Oncology, Rigshospitalet, Copenhagen, Denmark"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Department of Oncology, Rigshospitalet, Copenhagen, Denmark","institution_ids":["https://openalex.org/I2802709434"]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5004172331","display_name":"Hans Skovgaard Poulsen","orcid":"https://orcid.org/0000-0002-9801-5387","observed_orcids":["https://orcid.org/0000-0002-9801-5387"]},"institutions":[{"id":"https://openalex.org/I2802709434","display_name":"Rigshospitalet","ror":"https://ror.org/03mchdq19","country_code":"DK","type":"healthcare","lineage":["https://openalex.org/I2802567020","https://openalex.org/I2802709434","https://openalex.org/I4210145385"]}],"countries":["DK"],"is_corresponding":false,"raw_author_name":"Hans Skovgaard Poulsen","raw_affiliation_strings":["Department of Oncology, Rigshospitalet, Copenhagen, Denmark"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Department of Oncology, Rigshospitalet, Copenhagen, Denmark","institution_ids":["https://openalex.org/I2802709434"]}]}],"institutions":[],"countries_distinct_count":1,"institutions_distinct_count":1,"corresponding_author_ids":[],"corresponding_institution_ids":["https://openalex.org/I2802709434"],"apc_list":null,"apc_paid":null,"fwci":6.4508,"has_fulltext":true,"cited_by_count":95,"citation_normalized_percentile":{"value":0.97779931,"is_in_top_1_percent":false,"is_in_top_10_percent":true},"cited_by_percentile_year":{"min":88,"max":100},"biblio":{"volume":"33","issue":"4","first_page":"1657","last_page":"60"},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T10129","display_name":"Glioma Diagnosis and Treatment","score":0.9994999766349792,"subfield":{"id":"https://openalex.org/subfields/2730","display_name":"Oncology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},"topics":[{"id":"https://openalex.org/T10129","display_name":"Glioma Diagnosis and Treatment","score":0.9994999766349792,"subfield":{"id":"https://openalex.org/subfields/2730","display_name":"Oncology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10422","display_name":"Angiogenesis and VEGF in Cancer","score":9.999999747378752e-05,"subfield":{"id":"https://openalex.org/subfields/1312","display_name":"Molecular Biology"},"field":{"id":"https://openalex.org/fields/13","display_name":"Biochemistry, Genetics and Molecular Biology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},{"id":"https://openalex.org/T10550","display_name":"Ovarian cancer diagnosis and treatment","score":0.0,"subfield":{"id":"https://openalex.org/subfields/2730","display_name":"Oncology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/recurrent-glioblastoma","display_name":"recurrent glioblastoma","score":0.9340000152587891},{"id":"https://openalex.org/keywords/bevacizumab","display_name":"bevacizumab","score":0.9860000014305115},{"id":"https://openalex.org/keywords/temsirolimus","display_name":"temsirolimus","score":1.0},{"id":"https://openalex.org/keywords/combination-therapy","display_name":"combination therapy","score":0.8119999766349792},{"id":"https://openalex.org/keywords/mtor-inhibition","display_name":"mTOR inhibition","score":0.8050000071525574},{"id":"https://openalex.org/keywords/vegf-inhibition","display_name":"VEGF inhibition","score":0.8730000257492065},{"id":"https://openalex.org/keywords/pten-mutation","display_name":"PTEN mutation","score":0.8069999814033508},{"id":"https://openalex.org/keywords/pi3k-akt-mtor-pathway","display_name":"PI3K/AKT/mTOR pathway","score":0.8859999775886536},{"id":"https://openalex.org/keywords/progression-free-survival","display_name":"progression-free survival","score":0.7979999780654907},{"id":"https://openalex.org/keywords/drug-safety","display_name":"drug safety","score":0.4790000021457672},{"id":"https://openalex.org/keywords/hypercholesterolemia","display_name":"hypercholesterolemia","score":0.7680000066757202},{"id":"https://openalex.org/keywords/thrombocytopenia","display_name":"thrombocytopenia","score":0.75},{"id":"https://openalex.org/keywords/biomarkers","display_name":"biomarkers","score":0.5189999938011169}],"concepts":[{"id":"https://openalex.org/C2777802072","wikidata":"https://www.wikidata.org/wiki/Q413299","display_name":"Bevacizumab","level":3,"score":0.8852540850639343},{"id":"https://openalex.org/C2776820818","wikidata":"https://www.wikidata.org/wiki/Q7699074","display_name":"Temsirolimus","level":5,"score":0.8784568309783936},{"id":"https://openalex.org/C2776194525","wikidata":"https://www.wikidata.org/wiki/Q282142","display_name":"Glioblastoma","level":2,"score":0.8581994771957397},{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.6268166303634644},{"id":"https://openalex.org/C143998085","wikidata":"https://www.wikidata.org/wiki/Q162555","display_name":"Oncology","level":1,"score":0.47782495617866516},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.40896281599998474},{"id":"https://openalex.org/C183713625","wikidata":"https://www.wikidata.org/wiki/Q5282002","display_name":"Discovery and development of mTOR inhibitors","level":4,"score":0.2983578145503998},{"id":"https://openalex.org/C502942594","wikidata":"https://www.wikidata.org/wiki/Q3421914","display_name":"Cancer research","level":1,"score":0.2560756802558899},{"id":"https://openalex.org/C2776694085","wikidata":"https://www.wikidata.org/wiki/Q974135","display_name":"Chemotherapy","level":2,"score":0.2422618269920349},{"id":"https://openalex.org/C86803240","wikidata":"https://www.wikidata.org/wiki/Q420","display_name":"Biology","level":0,"score":0.11448705196380615},{"id":"https://openalex.org/C86554907","wikidata":"https://www.wikidata.org/wiki/Q285613","display_name":"PI3K/AKT/mTOR pathway","level":3,"score":0.06595072150230408},{"id":"https://openalex.org/C55493867","wikidata":"https://www.wikidata.org/wiki/Q7094","display_name":"Biochemistry","level":1,"score":0.0},{"id":"https://openalex.org/C190283241","wikidata":"https://www.wikidata.org/wiki/Q14599311","display_name":"Apoptosis","level":2,"score":0.0}],"mesh":[{"descriptor_ui":"D000068258","descriptor_name":"Bevacizumab","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D000328","descriptor_name":"Adult","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D000368","descriptor_name":"Aged","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D000971","descriptor_name":"Antineoplastic Combined Chemotherapy Protocols","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":true},{"descriptor_ui":"D001932","descriptor_name":"Brain Neoplasms","qualifier_ui":"Q000188","qualifier_name":"drug therapy","is_major_topic":true},{"descriptor_ui":"D001932","descriptor_name":"Brain Neoplasms","qualifier_ui":"Q000401","qualifier_name":"mortality","is_major_topic":false},{"descriptor_ui":"D001932","descriptor_name":"Brain Neoplasms","qualifier_ui":"Q000473","qualifier_name":"pathology","is_major_topic":false},{"descriptor_ui":"D005260","descriptor_name":"Female","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D005500","descriptor_name":"Follow-Up Studies","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D005909","descriptor_name":"Glioblastoma","qualifier_ui":"Q000188","qualifier_name":"drug therapy","is_major_topic":true},{"descriptor_ui":"D005909","descriptor_name":"Glioblastoma","qualifier_ui":"Q000401","qualifier_name":"mortality","is_major_topic":false},{"descriptor_ui":"D005909","descriptor_name":"Glioblastoma","qualifier_ui":"Q000473","qualifier_name":"pathology","is_major_topic":false},{"descriptor_ui":"D006801","descriptor_name":"Humans","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D008297","descriptor_name":"Male","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D008875","descriptor_name":"Middle Aged","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D009364","descriptor_name":"Neoplasm Recurrence, Local","qualifier_ui":"Q000188","qualifier_name":"drug therapy","is_major_topic":true},{"descriptor_ui":"D009364","descriptor_name":"Neoplasm Recurrence, Local","qualifier_ui":"Q000401","qualifier_name":"mortality","is_major_topic":false},{"descriptor_ui":"D009364","descriptor_name":"Neoplasm Recurrence, Local","qualifier_ui":"Q000473","qualifier_name":"pathology","is_major_topic":false},{"descriptor_ui":"D009367","descriptor_name":"Neoplasm Staging","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D011379","descriptor_name":"Prognosis","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D015996","descriptor_name":"Survival Rate","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D020123","descriptor_name":"Sirolimus","qualifier_ui":"Q000008","qualifier_name":"administration & dosage","is_major_topic":false},{"descriptor_ui":"D020123","descriptor_name":"Sirolimus","qualifier_ui":"Q000031","qualifier_name":"analogs & derivatives","is_major_topic":false},{"descriptor_ui":"D055815","descriptor_name":"Young Adult","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D061067","descriptor_name":"Antibodies, Monoclonal, Humanized","qualifier_ui":"Q000008","qualifier_name":"administration & dosage","is_major_topic":false}],"locations_count":4,"locations":[{"id":"pmid:23564811","doi":null,"is_oa":false,"landing_page_url":"https://pubmed.ncbi.nlm.nih.gov/23564811","pdf_url":null,"source":{"id":"https://openalex.org/S4306525036","display_name":"PubMed","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Anticancer research","raw_type":"Clinical Trial, Phase II"},{"id":"pmh:oai:pure.atira.dk:openaire_cris_publications/c66a065d-e95b-4e14-9510-119e6836deac","doi":null,"is_oa":false,"landing_page_url":"https://researchprofiles.ku.dk/da/publications/c66a065d-e95b-4e14-9510-119e6836deac","pdf_url":null,"source":{"id":"https://openalex.org/S4306401983","display_name":"Research at the University of Copenhagen (University of Copenhagen)","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I124055696","host_organization_name":"University of Copenhagen","host_organization_lineage":["https://openalex.org/I124055696"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Lassen, U, Sorensen, M, Gaziel, T B, Hasselbalch, B & Poulsen, H S 2013, 'Phase II study of bevacizumab and temsirolimus combination therapy for recurrent glioblastoma multiforme', Anticancer Research, vol. 33, no. 4, pp. 1657-60.","raw_type":"info:eu-repo/semantics/article"},{"id":"pmh:oai:pure.atira.dk:openaire_cris_publications/12dd85c8-275a-4d2d-8ad7-e27efb2ad121","doi":null,"is_oa":false,"landing_page_url":"https://researchprofiles.ku.dk/da/publications/12dd85c8-275a-4d2d-8ad7-e27efb2ad121","pdf_url":null,"source":{"id":"https://openalex.org/S4306401983","display_name":"Research at the University of Copenhagen (University of Copenhagen)","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I124055696","host_organization_name":"University of Copenhagen","host_organization_lineage":["https://openalex.org/I124055696"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"submittedVersion","is_accepted":false,"is_published":false,"raw_source_name":"Lassen, U, Sorensen, M, Gaziel, T B, Hasselbalch, B & Poulsen, H S 2013, 'Phase II study of bevacizumab and temsirolimus combination therapy for recurrent glioblastoma multiforme', Anticancer Research, vol. 33, no. 4, pp. 1657-1660. < http://ar.iiarjournals.org/content/33/4/1657.full.pdf+html >","raw_type":"info:eu-repo/semantics/article"},{"id":"mag:2118915687","doi":null,"is_oa":false,"landing_page_url":"https://pubmed.ncbi.nlm.nih.gov/23564811","pdf_url":null,"source":{"id":"https://openalex.org/S4306525036","display_name":"PubMed","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":null,"is_accepted":false,"is_published":false,"raw_source_name":"PubMed","raw_type":null}],"best_oa_location":null,"sustainable_development_goals":[{"display_name":"Good health and well-being","id":"https://metadata.un.org/sdg/3","score":0.9940000176429749}],"study_designs":[{"display_name":"Clinical Trial","id":"https://openalex.org/study-designs/clinical-trial"}],"awards":[],"funders":[],"has_content":{"grobid_xml":false,"pdf":false},"content_urls":null,"referenced_works_count":14,"referenced_works":["https://openalex.org/W1555073840","https://openalex.org/W1984461699","https://openalex.org/W1986154258","https://openalex.org/W2024586523","https://openalex.org/W2042692181","https://openalex.org/W2047945986","https://openalex.org/W2085295027","https://openalex.org/W2098176107","https://openalex.org/W2114438728","https://openalex.org/W2126783165","https://openalex.org/W2127931911","https://openalex.org/W2140885542","https://openalex.org/W2147775209","https://openalex.org/W2225154633"],"related_works":["https://openalex.org/W2196951954","https://openalex.org/W2274654215","https://openalex.org/W2047138539","https://openalex.org/W566773017","https://openalex.org/W90290088","https://openalex.org/W57783008","https://openalex.org/W7100242144","https://openalex.org/W2167923186","https://openalex.org/W2259871202","https://openalex.org/W2232426824"],"abstract_inverted_index":{"BACKGROUND:":[0],"Bevacizumab":[1],"combined":[2],"with":[3,50,63,83,95,100,116,258,302,316],"chemotherapy":[4],"has":[5,57,77],"recently":[6],"shown":[7],"promising":[8],"efficacy":[9],"in":[10,20,60,93,105,300,314],"recurrent":[11],"high-grade":[12],"glioma.":[13],"Phosphatase":[14],"and":[15,40,47,70,123,135,137,165,176,185,205,245,268,291],"tensin":[16],"homolog":[17],"(PTEN)":[18],"mutation":[19],"glioblastoma":[21],"multiforme":[22],"(GBM)":[23],"patients":[24,99,115,193,223,232,315],"causes":[25],"abnormally":[26],"high":[27],"activity":[28,309],"of":[29,32,44,68,187,230,310],"the":[30,41,84,161,188,201,217,269],"pathways":[31],"Phosphatidylinositide":[33],"3-kinases":[34],"(PI3K),":[35],"Protein":[36],"Kinase":[37],"B":[38],"(AKT),":[39],"mammalian":[42],"target":[43],"rapamycin":[45],"(mTOR)":[46],"is":[48],"associated":[49],"unfavorable":[51],"prognosis.":[52],"Temsirolimus,":[53],"an":[54,106,253],"mTOR":[55],"inhibitor,":[56],"been":[58,80],"well-tolerated":[59],"monotherapy,":[61],"but":[62,82],"limited":[64],"effects.":[65],"The":[66,168,208,238],"combination":[67,94,301,313],"temsirolimus":[69,87,128],"antibodies":[71],"to":[72,216,262,307],"vascular":[73],"endothelial":[74],"factor":[75],"(VEGF)":[76],"not":[78],"yet":[79],"investigated,":[81],"hypothesis":[85],"that":[86],"might":[88],"provide":[89],"complimentary":[90],"therapeutic":[91],"benefit":[92],"bevacizumab,":[96],"we":[97],"included":[98,282],"progressive":[101,317],"GBM":[102,117,318],"after":[103,119],"bevacizumab":[104,138,320],"open":[107],"phase":[108],"II":[109],"study.":[110],"PATIENTS":[111],"AND":[112],"METHODS:":[113],"Adult":[114],"recurrence":[118],"standard":[120],"temozolomide":[121],"chemoradiotherapy":[122],"bevacizumab-containing":[124],"second-line":[125],"therapy,":[126],"received":[127],"(25":[129],"mg":[130],"i.v.)":[131],"on":[132,141],"days":[133],"1":[134],"8":[136],"(10":[139],"mg/kg)":[140],"day":[142],"8,":[143],"every":[144,150],"two":[145],"weeks.":[146,152,249],"Assessments":[147],"were":[148,157,179,194,206,266],"performed":[149],"eight":[151,163,243],"Blood":[153],"samples":[154],"for":[155,160],"biomarkers":[156],"collected":[158],"weekly":[159],"first":[162,202],"weeks":[164,204],"at":[166,212],"progression.":[167],"primary":[169],"end-point":[170],"was":[171,210,242,247,275],"median":[172,239],"progression-free":[173],"survival":[174,183,241],"(PFS)":[175],"secondary":[177],"end-points":[178],"radiographic":[180],"response,":[181],"overall":[182],"(OS),":[184],"safety":[186],"bevacizumab-temsirolimus":[189],"combination.":[190],"RESULTS:":[191],"Thirteen":[192],"included,":[195],"whereof":[196],"three":[197],"went":[198],"off-study":[199],"during":[200],"four":[203],"replaced.":[207],"trial":[209],"terminated":[211],"13":[213],"patients,":[214],"according":[215],"planned":[218],"two-stage":[219],"design,":[220],"because":[221],"0/10":[222],"obtained":[224,233],"partial":[225],"remission":[226],"(PR).":[227],"Two":[228],"out":[229],"10":[231],"radiological":[234],"stable":[235],"disease":[236],"(SD).":[237],"PFS":[240],"weeks,":[244],"OS":[246],"15":[248],"One":[250],"patient":[251],"had":[252],"serious":[254],"adverse":[255],"event":[256],"(SAE)":[257],"a":[259,312],"hypersensitive":[260],"reaction":[261],"temsirolimus;":[263],"overall,":[264],"side-effects":[265,281],"mild,":[267],"most":[270],"common":[271],"grade":[272,279],"III":[273,280],"side-effect":[274],"hypercholesterolaemia":[276],"(4/10).":[277],"Other":[278],"hypertriglyceridaemia":[283],"(1/10),":[284,286,288,290],"thrombocytopenia":[285],"infection":[287],"hypertension":[289],"hyperglycemia":[292],"(1/10).":[293],"CONCLUSION:":[294],"Temsirolimus":[295],"can":[296],"be":[297],"safely":[298],"administered":[299],"bevacizumab.":[303],"This":[304],"study":[305],"failed":[306],"detect":[308],"such":[311],"beyond":[319],"therapy.":[321]},"counts_by_year":[{"year":2025,"cited_by_count":3},{"year":2024,"cited_by_count":4},{"year":2023,"cited_by_count":6},{"year":2022,"cited_by_count":3},{"year":2021,"cited_by_count":9},{"year":2020,"cited_by_count":4},{"year":2019,"cited_by_count":6},{"year":2018,"cited_by_count":7},{"year":2017,"cited_by_count":13},{"year":2016,"cited_by_count":14},{"year":2015,"cited_by_count":9},{"year":2014,"cited_by_count":15},{"year":2013,"cited_by_count":1}],"updated_date":"2026-11-04T10:54:05.112534","created_date":"2016-06-24T00:00:00"}